JPRN-UMIN000001529Completed未知
Phase II trial of irinotecan plus cisplatin for pretreated patients with Ewing sarcoma and PNET - EFT-CPT-CDDP
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Enrollment
- 32
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1)Patient who have no indication for chemotherapy
Investigators
Similar Trials
Recruiting
Phase 2
Phase II Study of cisplatin plus irinotecan for large cell neuroendocrine carcinomaarge cell neuroendocrine carcinomaJPRN-UMIN000004796ational Cancer Research Center Hospital East44
Completed
Phase 2
phase II study of irinotecan plus cisplatin followed by amrubicin in patients with extensive disease small-cell lung cancer.extensive disease small-cell lung cancerJPRN-C000000113West Japan Oncology Group45
Completed
Phase 2
Phase II study of nedaplatin plus irinotecan for stage III/IV squamous cell lung cancer (TORG0910)JPRN-UMIN000003330Thoracic Oncology Research Group (TORG)50
Completed
Phase 2
A phase II study of nedaplatin plus irinotecan for stage III/IV and EGFR mutation negative non-small cell lung cancer with high-risk factorsJPRN-UMIN000003622Kanagawa Cancer Center35
Completed
Not Applicable
Phase I study of irinotecan and cisplatin with concurrent thoracic radiotherapy in patients with limited-disease small cell lung cancerCancerLung CancerISRCTN75771514Erasmus Medical Centre (The Netherlands)9